# Ata Gh Ch Monitoring

> Monitors euthyroid adults with growth hormone deficiency (GHD) who are initiating GH replacement therapy for the development of central hypothyroidism (CH). Initiates levothyroxine (L-T4) if free thyroxine (fT4) falls below the laboratory reference range; triggers include GHD patient starting GH replacement.

- Skill: `dromlakhani/ata-gh-ch-monitoring` (Agent Skill)
- Install (CLI): `npx skillmds add dromlakhani/ata-gh-ch-monitoring`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/ata-gh-ch-monitoring/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Marketing & Growth
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-08-19
- Page: https://skillmd.com/skills/dromlakhani/ata-gh-ch-monitoring

---


# Monitor for central hypothyroidism development in GH-treated patients

## STEP 1 — Gather Information
Confirm GHD diagnosis (failed GH stimulation test or low IGF-1 with clinical features). Obtain baseline thyroid panel: fT4 and TSH. Verify euthyroid status (fT4 within lab reference range, TSH normal or low-normal). Record patient age, weight, and concomitant medications.

## STEP 2 — Rule In / Rule Out
Is baseline fT4 below the laboratory reference range? If yes, patient already has CH; treat per CH guideline and stop this pathway. If fT4 is within reference range, proceed to monitor for CH development during GH therapy.

## STEP 3 — Classify or Stratify
After initiating GH, measure fT4 at 6–8 weeks and then every 6 months. Classify result: fT4 decreased below reference range → CH developing; fT4 remains within reference range → no CH evident; continue routine monitoring.

## STEP 4 — Decide
If fT4 is below reference range, start L-T4 therapy at approximately 1.6 µg/kg/d (adjust for age, weight, clinical context) and titrate to maintain fT4 in the mid-to-upper half of the reference range. If fT4 remains normal, continue GH therapy and repeat fT4 monitoring per schedule.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on TSH alone to diagnose or monitor CH in GH-treated patients. Avoid initiating L-T4 empirically without a documented fT4 decrease below reference. Ensure adrenal insufficiency is evaluated or treated before starting L-T4 if not already addressed. Watch for overtreatment signs (elevated fT4, symptoms of hyperthyroidism) and adjust dose downward.

## Concrete Clinical Example
A 45-year-old male with confirmed GHD (IGF-1 -2 SD, subnormal GH stimulation) begins GH 0.3 mg/day. Baseline fT4 1.2 ng/dl (ref 0.9–1.7), TSH 2.0 µIU/ml. At 8 weeks, fT4 0.8 ng/dl (below reference). He is started on L-T4 1.2 µg/kg/d (~80 µg daily); repeat fT4 in 6 weeks shows 1.1 ng/dl within target range.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118